In addition, METTL13 inhibited the progression of clear cell renal cell carcinoma through phosphatidylinositol 3-kinase/protein kinase B (AKT)/mammalian target of the rapamycin/hypoxia-inducible factor-1 alpha pathway.10 In HCC, hematological and neurological expressed 1-like (HN1L)-mediated transcription axis activator protein 2 gamma/METTL13/transcription factor 3 zinc finger E-box-binding homeobox 1 has a driving effect on tumor growth and metastasis.6 As a possible therapeutic target for cancer, it is necessary to investigate the action of METTL13 in HCC. This evidence concerns the gene AKT1 and clear cell renal carcinoma.